Artelo Biosciences (ARTL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Key highlights and strategic direction

• Focus on novel lipid signaling modulation therapies for anorexia, cancer, anxiety, inflammation, and pain.

• Near-term catalysts expected over the next 6, 12, and 18 months, including multiple clinical milestones.

• Targeting billion-dollar markets, enhancing attractiveness for investment and partnerships.

• Robust patent estate with nearly 40 issued patents and another 40 pending.

• Experienced leadership team with extensive biopharmaceutical expertise.

Clinical pipeline and development updates

• Lead program ART-2713 is in phase 2 for cancer-related anorexia; data expected early next year.

• ART-2612, a FABP5 inhibitor, recently cleared by FDA for human studies; phase 1 to begin soon.

• ART-1211 (CBD-TMP co-crystal) targets anxiety and depression, with phase 1 data anticipated next year.

• Four major clinical milestones expected in the next 18 months across the pipeline.

• CARES trial evaluating lean body mass, weight gain, appetite, safety, and quality of life in cancer patients.

Scientific and clinical insights

• ART-2713 is a peripherally selective cannabinoid receptor agonist, designed to stimulate appetite without psychoactive effects.

• Phase 1 and 2 studies show favorable safety profile, with no grade 3/4 toxicities or discontinuations.

• ART-2612 shows promise in preclinical models for pain and inflammation, with high safety margins.

• ART-1211 demonstrates improved bioavailability and efficacy over CBD alone in preclinical anxiety and depression models.

• Patent protection for ART-1211 extends through 2038, supporting long-term exclusivity.